Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT03761108 Recruiting - Multiple Myeloma Clinical Trials

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

LINKER-MM1
Start date: January 23, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: - Side effects that may be experienced by people receiving REGN5458 - How REGN5458 works in the body - How much REGN5458 is present in the blood - How REGN5458 may work to treat cancer

NCT ID: NCT03759093 Recruiting - Multiple Myeloma Clinical Trials

CURATE.AI Optimized Modulation for Multiple Myeloma

Start date: September 10, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Clinical trial applying CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, to Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide dosing in multiple myeloma patients to show improvement in response.

NCT ID: NCT03758417 Recruiting - Multiple Myeloma Clinical Trials

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

CARTIFAN-1
Start date: January 23, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.

NCT ID: NCT03757221 Recruiting - Multiple Myeloma Clinical Trials

Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

IDARA
Start date: February 7, 2019
Phase: Phase 2
Study type: Interventional

Multiple myeloma is an incurable hematological malignancy that affects older patients. Currently, despite recent progress, the disease relapses more or less quickly after initial treatment and requires the resumption of treatment with new drugs associated with cortisone, whose side effects are important. The investigators propose to conduct a phase 2 testing the combination ixazomib - daratumumab without dexamethasone.

NCT ID: NCT03756896 Active, not recruiting - Plasma Cell Myeloma Clinical Trials

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Start date: January 25, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, pomalidomide, and dexamethasone may work better in treating patients with multiple myeloma.

NCT ID: NCT03755154 Completed - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Start date: July 17, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this first in human study is to assess safety, tolerability, Pharmacokinetic (PK) and preliminary clinical activity and to estimate the Maximum Tolerated Doses (MTD(s))/ Recommended Phase 2 Doses (RP2D(s)) of S65487 as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) or Chronic Lymphocytic Leukemia (CLL).

NCT ID: NCT03752541 Suspended - Multiple Myeloma Clinical Trials

Efficacy and Safety Evaluation of BCMA-UCART

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.

NCT ID: NCT03751293 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Start date: January 8, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

NCT ID: NCT03748953 Completed - Multiple Myeloma Clinical Trials

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

Start date: January 24, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.

NCT ID: NCT03746652 Not yet recruiting - Multiple Myeloma Clinical Trials

Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

DARIA
Start date: December 2018
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients.